A 35-year-old 
Introduction

Langerhans cell histiocytosis (LCH) is a rare disorder of uncertain etiology, characterized by a wide clinical spectrum and varied behavior. Recent biological studies have shown that systemic LCH is a clonal proliferative disorder (1), and positive responses with several chemotherapeutic agents have been reported (2, 3). In contrast with systemic LCH, pulmonary LCH (PLCH) occurs almost exclusively in adult smokers. These patients often improve spontaneously or enter remission once smoking is stopped (4, 5). Molecular analysis has revealed that this disease is usually nonclonal, indicating that inflammatory processes are involved in the development of PLCH (4).
Here 
F i g u r e 3 . Hi s t o p a t h o l o g i c a l f i n d i n g s o f t h e b i o p s y s p e c i me n s o b t a i n e d f r o m t h e l u n g ( A) a n d t h e l i v e r ( B ) . Gr a n u l o ma t o u s l e s i o n s c o n s i s t i n g o f h i s t i o c y t e s a n d e o s i n o p h i l i n f i l t r a t i o n a r e p r e s e n t ( A, B : HE s t a i n × 8 0 0 ) . the central nervous system and whole bone scintigraphy displayed no abnormalities. Based on radiographic findings and smoking history of the patient, PLCH was suspected. On pathological examination of thoracoscopic lung and liver biopsy specimens, granulomatous lesions displayed CD1 and S-100 protein-positive histiocytes with infiltration of eosinophils and fibrous lesions (Fig. 3, immunohistochemical staining for CD1 and S-100; not shown). A diagnosis of LCH was thus established.
F i g u r e 4 . F i n d i n g s f r o m c h e s t a n d a b d o mi n a l CT i n Au g u s t 1 9 9 8 , 2 mo n t h s a f t e r d i a g n o s i s ( 2 mo n t h s a f t e r s mo k i n g c e s s a t i o n ) . Di f f u s e n o d u l a r l u n g s h a d o ws t h a t h a v e i n c r e a s e d i n s i z e a n d d e c r e a s e d l i v e r i n v o l v e me n t i s e v i d e n t .
F i g u r e 5 . Ch e s t a n d a b d o mi n a l CT f i n d i n g s i n J u n e 1 9 9 9 d u r i n g t a p e r i n g o f p r e d n i s o l o n e ( 7 . 5 mg / d a y ) . He p a t i c n o d u l a r s h a d o ws t h a t i n c r e a s e d i n s i z e a n d p u l mo n a r y c y s t i c n o d u l e s t h a t d i d n o t i n c r e a s e i n s i z e a r e e v i d e n t .
F i g u r e 6 . Ab d o mi n a l CT f i n d i n g s i n J u n e 2 0 0 0 , 1 0 mo n t h s a f t e r i n i t i a t i n g p u l s e t h e r a p y d u r i n g t h e t a p e r i n g o f p r e d n i s o l o n e ( 1 5 mg / d a y ) . T h e h e p a t i c n o d u l a r s h a d o ws c a n b e s e e n t o h a v e a g a i n i n c r e a s e d i n s i z e .
Despite cessation of smoking, diffuse nodular lung shadows had increased in size at 2 months after diagnosis (Fig. 4) , although liver involvement improved (Fig. 4) (Fig. 7) .
F i g u r e 7 . F i n d i n g s f r o m c h e s t a n d a b d o mi n a l CT i n 2 0 0 6 , f i v e y e a r s a f t e r t h e t r e a t me n t wi t h e t o p o s i d e . T h e l i v e r l e s i o n s h a v e ma r k e d l y d e c r e a s e d i n s i z e a n d n u mb e r .
Discussion
Although 
